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Abstract
Introduction Discriminating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) from cardiogenic
pulmonary edema (CPE) using the plasma level of brain natriuretic peptide (BNP) alone remains controversial. The
aim of this study was to determine the diagnostic utility of combination measurements of BNP and C-reactive
protein (CRP) in critically ill patients with pulmonary edema.
Methods: This was a cross-sectional study. BNP and CRP data from 147 patients who presented to the emergency
department due to acute respiratory failure with bilateral pulmonary infiltrates were analyzed.
Results: There were 53 patients with ALI/ARDS, 71 with CPE, and 23 with mixed edema. Median BNP and CRP levels
were 202 (interquartile range 95-439) pg/mL and 119 (62-165) mg/L in ALI/ARDS, and 691 (416-1,194) pg/mL (p <
0.001) and 8 (2-42) mg/L (p < 0.001) in CPE. BNP or CRP alone offered good discriminatory performance (C-statistics
0.831 and 0.887), but the combination offered greater one [C-statistics 0.931 (p < 0.001 versus BNP) (p = 0.030 versus
CRP)]. In multiple logistic-regression, BNP and CRP were independent predictors for the diagnosis after adjusting for
other variables.
Conclusions: Measurement of CRP is useful as well as that of BNP for distinguishing ALI/ARDS from CPE.
Furthermore, a combination of BNP and CRP can provide higher accuracy for the diagnosis.
Introduction
Acute hypoxic respiratory failure due to pulmonary edema
is a common reason for visiting the emergency depart-
ment. The distinction between cardiogenic pulmonary
edema (CPE) and acute lung injury (ALI) or acute respira-
tory distress syndrome (ARDS) is clinically important
because the management and the prognosis are different
[1]. Hence, possible biomarkers for the differential diagno-
sis have been investigated using various strategies [2-5].
The most widely used clinical definition of ALI/ARDS is
based on the acute onset of respiratory failure, bilateral
infiltration on chest radiography, a pulmonary capillary
wedge pressure (PCWP) < 18 mmHg, or absence of clini-
cal evidence of elevated left atrial pressure [2]. However,
clinical estimation of PCWP is notoriously inaccurate [6],
relatively invasive and costly [7], has no clear evidence of
benefits [8,9], and may result in potentially adverse clinical
outcomes [10]. Moreover, ALI/ARDS with concomitant
heart failure complicates the differential diagnosis [11,12].
If the respiratory status rapidly improves after the admin-
istration of diuretics alone, CPE should be considered,
whereas patients who have poor responses to sufficient
diuresis should be considered to have non-cardiogenic
pulmonary edema. In patients with CPE that was triggered
by an airway infection, the respiratory status might not
completely improve in response to diuretic treatment, if
airway an infection itself influences this status to some
degree. Therefore, these patients who cannot undergo
invasive examinations, such as bronchoscopy because of
poor respiratory conditions, tend to only be diagnosed
after the start of treatment [13-16]. However, making an
accurate initial diagnosis is still important in the emer-
gency department, and the alternative tools for use in
maing a differential diagnosis have been explored using
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any medium, provided the original work is properly cited.various strategies [17], including the measurement of the
alveolar protein concentration [5], as well as the use of
chest radiographs [13,14] and echocardiography [18].
Brain natriuretic peptide (BNP) is released from the
cardiac ventricles in response to increased cardiac wall
tension. Rapid measurement of BNP has been shown to
be a sensitive marker of dyspnea due to cardiac causes
in the emergency room and intensive care unit settings
[19-21]. In critically ill patients with hypoxic respiratory
failure due to CPE versus ALI/ARDS, the diagnostic uti-
lity of BNP has been extensively investigated [15,16,22],
however, the accuracy of discriminating these two disor-
ders by the BNP level alone is still a matter of debate.
Several investigators have reported that BNP levels do
not accurately discriminate CPE from sepsis [23-25].
Severe sepsis, known as one cause of ALI/ARDS, can
increase BNP levels in spite of a normal cardiac function
[24]. Therefore, false-positive findings of plasma BNP
levels may be found in sepsis-associated ALI/ARDS
patients.
On the other hand, C-reactive protein (CRP) is an
acute phase protein produced primarily from the liver
and is stimulated by the release of cytokines, such as
interleukin-6 [26]. CRP is a marker of systematic inflam-
mation that is elevated by a wide variety of diseases
[27,28], and is widely-used at numerous emergency
departments. The severe inflammatory process of the
lung in ALI/ARDS patients occurs in response to various
etiologies, including pulmonary or extrapulmonary injury
[29]. Although there have been a few reported studies
regarding the CRP levels [27,30] in critically ill patients
with ALI/ARDS, the differential diagnostic value of CRP
for these conditions has not been determined. Further-
more, the utility of using a combination of BNP and CRP
has not been examined for the differential diagnosis of
ALI/ARDS and CPE.
We therefore assessed the diagnostic utility of measur-
ing the plasma BNP levels combined with CRP levels in
patients with hypoxic acute respiratory failure due to
CPE versus ALI/ARDS.
Materials and methods
Setting and patients
This was a single-center cross-sectional study. The proto-
col was approved by the institutional review boards of the
Aso Iizuka Hospital, and informed consent for participa-
tion was obtained from each patient or a surrogate deci-
sion maker. The hospital is a large teaching hospital with
1,600 inpatient beds. The emergency physicians routinely
measured BNP and CRP levels in the plasma of the emer-
gency outpatients, who met the following criteria: presen-
tation with acute respiratory failure with a PaO2/fraction
of inspired oxygen (FiO2) ≤ 300 [2], bilateral pulmonary
infiltrates on chest radiography, and age ≥18 years,
between May 2004 and March 2010 at the emergency
department. The patients who had the following diag-
n o s e so rd i s e a s ec o n d i t i o n so n admission were excluded
from this study: previously-detected interstitial pneumo-
nia, severe bronchial asthma (stage III or more severe
disease based on the criteria of the Global Initiative for
Asthma [31]) or chronic obstructive pulmonary disease
(stage III or more severe based on the criteria of the Glo-
bal Initiative for Chronic Obstructive Lung Disease [32]),
distinct acute coronary syndrome, renal failure requiring
dialysis, cardiac surgery within 2 months, a preexisting
decrease of the left ventricular ejection fraction (LVEF: <
30%), malignancies such as lung cancer and lymphoma,
intracranial hemorrhage, or cardio-pulmonary arrest in
the emergency room.
We designed the study to have a 90% power (b-level =
0.01) with an a-level of 0.05 to show that the AUC of
0.75 for either the CRP or BNP test is significant from
the null hypothesis value of 0.5. A total of 106 subjects
(53 subjects in each group) are required [33].
The baseline characteristics recorded at the time of
enrollment included the following: patient demographics,
past medical history including affectors for CRP produci-
bility (e.g. chronic hepatic failure and receiving corticos-
teroids), blood pressure, heart rate, body temperature, S3
gallop, PaO2/FiO2, white blood cell count, renal function,
culture results, echocardiographic findings, hemody-
namics, Acute Physiology and Chronic Health Evaluation
(APACHE) II score, and the need for mechanical ventila-
tion including non-invasive positive pressure ventilation.
Determination of the final diagnosis
The frequency of RHC examinations for estimating the
PCWP has now decreased, because there is no clear evi-
dence of benefit [8,9]. We therefore determined the final
diagnosis according to the clinical features and responses
to treatments. As shown in Table 1, the clinical diagnos-
tic criteria were originally defined to ensure the objectiv-
ity of determining the final diagnosis.
First of all, if RHC was examined, the measured value
was required for each diagnosis, CPE or ALI/ARDS [2].
Next, the evidence for infection, culture result and/or
immunological test was required. This requirement must
be cautiously considered. The subjects with ALI/ARDS
include non-infectious causes such as pancreatitis or
trauma [2], moreover, not all infections are always con-
firmed by culture results and/or immunological tests. As
a result, this condition was set as a requirement for the
diagnosis of ALI/ARDS. In contrast, for the diagnosis of
CPE in the present study, this condition was set as an
absolute prerequisite in order to rule out the patients
with CPE which was triggered by infections as much as
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respond to mixed-type edema. Immunological tests for
infections included polymerase chain reaction assays for
Pneumocystis jiroveci and acid-fast bacillus, a Cytomega-
lovirus antigenemia assay, and rapid detection kits for
serum Mycoplasma pneumoniae antibody and urinary
antigens of Streptococcus pneumoniae and Legionella
pneumophila. In additon, heart failure was divided to two
types, namely systolic dysfunction or diastolic dysfunc-
tion [34], and therefore the condition of No. 3 (Table 1)
was stipulated. The presence of pleural effusion on chest
radiographs, which was more frequently seen in patients
with CPE than those with ALI/ARDS [13,14], and an
improvement in the respiratory status with diuresis [15]
were also included in these criteria. However, each find-
ing was not absolute for determining the diagnosis. We
therefore established multiple options, the CPE subjects
were required No. 1 and No. 2, together with at least two
features in Nos. 3-5, ALI/ARDS ones were required No.1,
together with at least three features in Nos. 2-5. The
patients who did not meet these diagnostic criteria were
categorized as mixed edema, and thus were excluded
from the analyses in this study. These classifications were
done by two independent physicians who were blinded to
the BNP and CRP data. Of the 147 total enrolled cases,
124 met the above-mentioned criteria, the other 23 cases
did not meet the criteria. As a result, 71 patients were
diagnosed with CPE, 53 patients with ALI/ARDS, and 23
patients with mixed type pulmonary edema.
Measurements of BNP and CRP
BNP levels in plasma were measured immediately after the
sample collection in the emergency room with a well-vali-
dated commercially available immunoassay (Tosoh,
Tokyo, Japan) with a detection limit of 4 pg/mL. CRP
levels in plasma were measured by a standard sensitive
Latex-immunoassay (Denka Seiken, Tokyo, Japan) with a
detection limit of 0.1 mg/L. The normal range for this
assay is < 10 mg/L. Both values in all patients were mea-
sured within 2 hrs after arriving at the emergency
department.
Statistical analysis
Statistical analyses were performed using the PASW sta-
tistics 18.0 software package (IBM SPSS, Tokyo, Japan),
except for comparison of the receiver operating charac-
teristic (ROC) curve, which was performed using the
STATA version 11 software package (Stata, College Sta-
tion, TX, US). Statistical significance was defined by a p
value < 0.05 for all analyses. Continuous variables were
tested for normality using the Shapiro-Wilk test, and
compared using the Student’s t-test or Mann-Whitney
test distribution. The chi-square test was applied for
comparing categorical variables, unless one of the cate-
gories had fewer than 20 observations, in which case,
the Fisher’s exact test was applied. For statistically dif-
ferent findings between CPE and ALI/ARDS groups, we
used multiple logistic regression analysis to compare the
relevant outcomes. Continuous variables were redefined
as dichotomous variables using the medians as cut-off
values in the study population, excluding mixed edema.
The sensitivity, specificity, positive predictive value,
negative predictive value, and diagnostic accuracy rates
were calculated according to standard definitions. The
accuracy of discriminatory performance was compared
by the area under ROC curves. The mixed type patients
were excluded for all statistical analyses, such as multi-
ple logistic regression and ROC curves with determina-
tion of the cut-off levels of BNP and CRP.
Results
Patient characteristics
Baseline characteristics and the results of laboratory and
clinical examinations of the 147 patients, who were stra-
tified according to their final diagnosis, are shown in
Table 2 and 3. The ALI/ARDS subjects included 7
patients with ALI and 46 patients with ARDS. Between
the ALI/ARDS and CPE groups, there was no statistical
difference in the age, gender, and frequency of a past
history of cardiac or pulmonary diseases. In the evalua-
tion of patients who had affectors for CRP producibility,
there were three patients (5.7%) in ALI/ARDS, and
seven patients (9.9%) in CPE, who had acute hepatic
Table 1 Criteria for the clinical diagnosis
No. Clinical features CPE ALI/ARDS
1 PCWP in right heart catheterization (if examined), mmHg > 18 ≤ 18
2 Culture results and/or immunological test for infections Negative Positive
3 LVEF < 50% and/or diastolic dysfunction on echocardiography Present Absent
4 Pleural effusion on chest radiographs Present Absent
5 PaO2 / FiO2 > 400 within 3 days after diuresis Present Absent
CPE subjects were required No. 1 and No.2, together with at least two features in Nos. 3-5.
ALI/ARDS subjects were required No.1, together with at least three features in Nos. 2-5.
The patients who did not meet these diagnostic criteria were categorized as having mixed edema,
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; CPE: cardiogenic pulmonary edema; LVEF: left ventricular ejection fraction; PCWP: pulmonary
capillary wedge pressure
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ALI/ARDS (n = 53) CPE (n = 71) Mixed (n = 23) p values for ALI/ARDS vs CPE
Patient demographics
age, yrs 78 (69-85) 81 (74-89) 81 (75-89) 0.083
male gender 34 (64) 35 (49) 13 (57) 0.100
History of cardiac disease
chronic heart failure 18 (34) 36 (51) 16 (70) 0.063
myocardial infarction 9 (17) 18 (25) 5 (22) 0.264
angina pectoris 4 (8) 7 (10) 2 (9) 0.654
prior PCI 3 (6) 7 (10) 3 (13) 0.606
prior CABG 4 (8) 5 (7) 3 (13) 0.915
History of diabetes mellitus 9 (17) 21 (30) 7 (30) 0.105
History of pulmonary disease
COPD 5 (9) 2 (3) 0 (0) 0.114
asthma 1 (2) 1 (1) 1 (4) 0.834
Physical examination
systolic blood pressure, mmHg 120 (100-146) 148 (126-170) 126 (110-156) < 0.001
diastolic blood pressure, mmHg 67 (54-83) 86 (70-100) 80 (64-89) < 0.001
heart rate, beats/min 100 (79-113) 108 (90-119) 104 (90-136) 0.109
body temperature,°F 98.6 (97.0-99.9) 98.1 (97.0-98.8) 98.6 (97.5-100.8) 0.483
S3 gallop 2 (4) 11 (15) 5 (22) 0.031
*Data are expressed as the number (%) or median (interquartile range).
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; CPE:
cardiogenic pulmonary edema; PCI: percutaneous coronary intervention; PCWP: pulmonary capillary wedge pressure
Table 3 Findings of laboratory and clinical examinations*
ALI/ARDS (n = 53) CPE (n = 71) Mixed (n = 23) p value for ALI/ARDS vs CPE
Laboratory findings
WBC count, ×1000/μL 10.4 (7.3-12.8) 9.6 (7.2-13.4) 9.8 (5.9-11.2) 0.587
CRP, mg/L 119 (62-165) 8 (2-42) 100 (36-184) < 0.001
BNP, pg/mL 202 (95-439) 691 (416-1194) 403 (221-1048) < 0.001
GFR, mL/min 60.8 (28.6-92.9) 46.0 (35.9-58.4) 56.2 (29.7-86.9) 0.056
PaO2/FiO2 100 (68-147) 111 (82-156) 166 (9-220) 0.322
Mechanical ventilation 34 (64) 35 (49) 9 (39) 0.100
APACHE II score 17 (16-19) 17 (16-18) 17 (16-18) 0.245
Positive culture results 28 (53) 0 (0) 0 (0) –
Chest radiography
number of patients examined 53 (100) 71 (100) 23 (100) –
infiltrates on two quadrants 24 (45) 38 (54) 18 (78) 0.468
infiltrates on four quadrants 28 (53) 33 (46) 6 (26) 0.604
pleural effusion 43 (81) 66 (93) 19 (83) 0.043
cardiomegaly 25 (47) 39 (55) 13 (57) 0.500
Echocardiography
number of patients examined 50 (94) 71 (100) 20 (87) –
LVEF, % 60 (56-66) 57 (45-69) 49 (39-65) 0.052
mitral regurgitation ≥grade 2 15/50 (30) 31/71 (44) 7/23 (30) 0.182
right ventricular dilation 13/50 (26) 29/71 (41) 8 (35) 0.135
Hemodynamics
number of patients examined 6 (11) 4 (6) 3 (10) 0.206
PCWP, mmHg 10 (9-13) 32 (28-37) 32 (26-34) 0.096
*Data are expressed as the number (%) or median (interquartile range).
ALI: acute lung injury; APACHE: acute physiology and chronic health evaluation; ARDS: acute respiratory distress syndrome; BNP: brain natriuretic peptide; CRP:
C-reactive protein; CPE: cardiogenic pulmonary edema; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; PCWP: pulmonary capillary wedge
pressure
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and two patients (2.8%) in CPE, who received corticos-
teroids. No significant differences were observed
between these prevalence rates (p = 0.31, p = 0.12,
respectively). The patients with CPE were more likely to
present with high systolic and diastolic blood pressure.
All patients with ALI/ARDS had high APACHE II
scores, in line with the findings of previous reports
[16,22]. Echocardiography was performed in 96% of
patients, but RHC was performed in only 13 cases (9%).
The etiology of the 53 patients with ALI/ARDS con-
sisted of 30 with intrapulmonary diseases [including 20
cases of acute pneumonia (38%) and 10 of aspiration
pneumonia (19%)] and 23 patients with extrapulmonary
diseases [including 20 with sepsis (38%), 1 with burns, 1
with severe pancreatitis, and 1 due to trauma].
BNP in patients with pulmonary edema
As shown in Table 3 and Figure 1A, the initial levels of
plasma BNP were significantly different between the
patients with CPE and ALI/ARDS. When patients with
ALI/ARDS were subclassified into those with sepsis or
without sepsis, no significant differences were observed
between the median (interquartile range; IQR) BNP
levels in patients with sepsis [299 (128-463) pg/mL] and
those without sepsis [115 (70-417) pg/mL]. The area
under the ROC curve (Figure 2) when BNP was used to
differentiate CPE from ALI/ARDS was 0.831 (p < 0.001).
A BNP cutoff value of 500 pg/mL (approximate values
as the highest likelihood ratio according to the ROC
curves, excluding the mixed type edema) had a sensitiv-
ity of 69.0%, a specificity of 83.1%, and an accuracy of
75.0% for detecting CPE (Table 4).
CRP in patients with pulmonary edema
The initial levels of plasma CRP in patients with ALI/
ARDS were significantly higher than those with CPE
( T a b l e3a n dF i g u r e1B ) .T h ea r e au n d e rt h eR O C
curve (Figure 2) when CRP was used to differentiate
CPE from ALI/ARDS was 0.887 (p < 0.001). A CRP cut-
off value of 50 mg/L (approximate values as the highest
likelihood ratio according to the ROC curves, excluding
the mixed type edema) had a sensitivity of 59.2%, a spe-
cificity of 69.8%, and an accuracy of 63.7% for detecting
ALI/ARDS (Table 4).
Predictors of the diagnosis after adjusting for other
variables
By means of multiple logistic-regression analyses, we
determined the additional diagnostic power of measure-
ment of BNP and CRP, patients’ age, systolic blood pres-
sure, S3 gallop, left ventricular ejection fraction, and the
presence of pleural effusion on the chest radiograph. In
order to increase the statistical power, continuous
variables were redefined as dichotomous variables using
t h ef o l l o w i n gc u t - o f fv a l u e s :a g eo f8 0y e a r s ,s y s t o l i c
blood pressure of 135 mmHg, left ventricular ejection
fraction of 60% (median of population, respectively), and
p l a s m al e v e l so fC R P5 0m g / La n dB N Po f5 0 0p g / m L
(approximate values as the highest likelihood ratio
according to the ROC curves, excluding the mixed type
edema). This model showed that higher levels of BNP
and lower levels of CRP were strong independent pre-
dictors of CPE (Table 5).
The value of combination measurements of BNP and CRP
in patients with pulmonary edema
As shown in Figure 2, the area under the ROC curve
when the combination of BNP and CRP was used to dif-
ferentiate CPE from ALI/ARDS was 0.931 (p < 0.001).
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Figure 1 Plasma concentrations of brain natriuretic peptide (BNP)
A) and C-reactive protein (CRP) B) in patients with cardiogenic
pulmonary edema (CPE) (n = 71), or acute lung injury/acute
respiratory distress syndrome (ALI/ARDS) with (n =5 3 ) .T h ep
values show between these subjects. The BNP levels in CPE patients
were higher than those in ALI/ARDS patients (p <0 . 0 0 1 ) .T h eC R P
levels in the ALI/ARDS patients were higher than those in the CPE
patients (p < 0.001).
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ROC curve between BNP alone and CRP alone (p =
0.201), while the combination of BNP and CRP offered
excellent performance compared with BNP alone
(p < 0.001) and CRP alone (p = 0.030). There was a
moderate correlation between the levels of BNP and
CRP (r = -0.414).
Discussion
This study is the first to demonstrate that a combination
of the measurement of BNP and CRP levels provides an
advantage over measurement of BNP or CRP levels alone
for the differential diagnosis of CPE and ALI/ARDS.
The present study demonstrated that BNP had good
diagnostic utility for distinguishing CPE from ALI/
ARDS, consistent with the previous reports [15,22]. The
AUC of BNP measurement for the diagnosis in our
study appeared to be higher than those in these previous
studies. This might have been due to the timing of the
examination. The BNP levels of all patients in our study
were measured within 2 hrs after visiting the emergency
room, while the median time from the recognition of
pulmonary edema to the measurement of BNP was 3
h r s( I Q R ;0 . 5t o1 4 )i nt h er e p o r tb yR a n ae ta l[ 1 5 ] .
BNP levels generally decrease after treatment for heart
failure [35], hence, the high levels and accuracy of our
study may be explained by our measurement of BNP
levels in most patients before starting treatment.
Several authors also have reported that BNP levels
cannot discriminate CPE from sepsis-induced ARDS
[23-25], because the plasma BNP level may increase due
to myocardial dysfunction or the direct effect of inflam-
matory mediators produced by myocytes in patients
with sepsis, in spite of their normal cardiac function
[36]. Our study showed no significant differences in the
plasma BNP levels between cases of ALI/ARDS with
sepsis and those without sepsis. However, the present
study population was relatively small, so it may be diffi-
cult to discriminate CPE and ALI/ARDS by using BNP
alone if the rate of sepsis is high. Additionally, the BNP
levels are also known to be elevated in part as a result
of the acute right heart dysfunction that is associated
with ARDS [37,38]. Increased stretching of the right
ventricle and atrium may cause BNP release, indepen-
dent of left ventricular filling pressure, in patients with
ARDS. In the present study, the frequency of right ven-
tricular dilation/hypokinesis when evaluated by the right
heart load in echocardiography was not significantly dif-
ferent between CPE and ALI/ARDS patients. However,
the evaluation using echocardiography was clinically dif-
ficult, and this was one limitation associated with this
study. If right heart dysfunction caused by ALI/ARDS
influences the plasma BNP levels, a differential diagnosis
of CPE versus ALI/ARDS would be extremely difficult
using the BNP level alone.
We also demonstrated the usefulness of measuring
CRP for distinguishing CPE from ALI/ARDS. Some
patients with ALI/ARDS could have severe community
$UHDXQGHUFXUYH FRQILGHQFHLQWHUYDO
%13  
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Figure 2 Receiver operating characteristics curve (AUC) analyses
of brain natriuretic peptide (BNP), C-reactive protein (CRP), and
BNP combined with CRP in discriminating cardiogenic pulmonary
edema (CPE) from acute lung injury/acute respiratory distress
syndrome (ALI/ARDS), excluding the mixed type of pulmonary
edema. CRP levels were converted to the negative values, because
lower CRP levels were expected to be more common in CPE patients.
p < 0.001 compared BNP alone with combination BNP and CRP;
p = 0.030 compared CRP alone with BNP and CRP.
Table 4 Performance characteristics of various cut off
points of BNP or CRP, excluding mixed type edema
Cut-off points Sensitivity Specificity PPV NPV Accuracy
BNP levels for CPE
≧400 80.3 66.0 76.0 71.4 74.2
≧500 69.0 83.1 84.5 66.7 75.0
≧600 60.6 84.9 84.3 61.6 71.0
CRP levels for ALI/ARDS
≧80 53.5 90.6 88.4 59.3 69.4
≧50 59.2 69.8 72.4 56.1 63.7
≧20 69.0 50.9 65.3 55.1 61.3
Cut-off points of BNP (pg/mL), CRP (mg/L), (%)
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; BNP: brain
natriuretic peptide; CRP: C-reactive protein; CPE: cardiogenic pulmonary
edema; NPV: negative predictive value; PPV: positive predictive value
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based on the CURB65 severity score for CAP [39].
Recent studies demonstrated that CRP is an indepen-
dent marker of the severity of CAP [40,41]. Therefore,
the CRP levels in patients with ALI/ARDS, including
severe pneumonia, may be useful for distinguishing
these cases from patients with CPE. Although the indivi-
dual measurements of BNP or CRP are effective for dif-
ferentiating ALI/ARDS from CPE, we found the
combination measurement of BNP and CRP to provide
better results compared with measuring either BNP or
CRP alone. Because the BNP level can increase in
patients with sepsis, our results suggest that measuring
both CRP and BNP can eliminate this drawback to the
measurement of BNP alone. Therefore, this combination
measurement will help physicians determine a differen-
tial diagnosis for critically ill patients with pulmonary
edema, even if the patients are suspected to have sepsis
or acute cor pulmonale induced by ALI/ARDS. As the
value of RHC, echocardiography, and the measurement
of BNP alone for the differential diagnosis is still contro-
versial, our results suggest that a combination of the
measurements of BNP and CRP may therefore be an
effective additional or alternative, non-invasive, and
inexpensive diagnostic strategy.
This study has several limitations. First, this study vali-
dated clinical diagnoses, because an objective “gold stan-
dard” method for diagnosis of ALI/ARDS is absent.
Although we performed a multiple logistic regression ana-
lysis and showed that BNP was an independent predictor,
the possibility of collinearity between each surrogate fea-
ture (such as PCWP or LVEF as listed in the clinical diag-
nostic criteria) and BNP cannot be completely ruled out.
Second, there was a relatively high number of mixed-type
cases of pulmonary edema, and these cases were excluded
for the statistical analyses. Finally, this study was limited to
a still small sample size at a single center.
In clinical practice, we occasionally provide treatment
concurrently targeting both CPE and ALI/ARDS for
critical patients. This is important in several cases, how-
ever, we must continue to challenge the differential
diagnosis of pulmonary edema in order to provide an
optimal treatment. Better diagnoses will lead to better
treatment and thereby contribute to better patient
outcomes.
Conclusions
This is the first report evaluating the utility of measur-
ing both CRP and BNP in plasma to provide a differen-
tial diagnosis in patients with pulmonary edema. Our
results indicate that measurement of CRP could be use-
ful as well as BNP for discriminating ALI/ARDS from
CPE. In addition, the evaluation of the combination of
C R Pa n dB N Pc a np r o v i d ea ne v e nh i g h e ra c c u r a c yf o r
the diagnosis. It is hoped that a large multi-center sur-
vey including cases of sepsis-induced ARDS can be
accomplished in the near future.
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Table 5 Predictors for distinguishing CPE from ALI/ARDS, excluding the mixed type*
univariate multivariate
Predictors for CPE OR 95%CI p-value OR 95%CI p-value
age > 80y 1.350 0.660-2.761 0.411 1.125 0.370-3.417 0.836
systolic BP > 135 mmHg 3.148 1.496-6.627 0.003 3.999 1.311-12.198 0.015
S3 gallop sound 4.032 0.845-19.251 0.080 9.142 0.727-115.032 0.087
CRP > 50 mg/L 0.083 0.035-0.196 < 0.001 0.106 0.035-0.323 < 0.001
BNP > 500 pg/mL 12.50 5.057-30.898 < 0.001 14.425 4.382-47.483 < 0.001
LVEF > 60% 0.474 0.223-1.006 0.052 0.799 0.258-2.476 0.697
Pleural effusion on chest radiograph 2.805 0.881-8.932 0.081 5.293 0.791-35.434 0.086
*Results of multiple logistic regression analysis.
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; BNP: brain natriuretic peptide; BP: blood pressure; CRP: C-reactive protein; CPE: cardiogenic
pulmonary edema; LVEF: left ventricular ejection fraction
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